TY - JOUR
T1 - Immunological basis in the pathogenesis and treatment of bladder cancer
AU - Thompson, David B.
AU - Siref, Larry E.
AU - Feloney, Michael P.
AU - Hauke, Ralph J.
AU - Agrawal, Devendra K.
N1 - Publisher Copyright:
© 2015 Informa UK, Ltd.
Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - The pathogenesis and transition of normal urothelium into bladder carcinoma are multifactorial processes. Chronic inflammation causes initiation and progression of the underlying pathophysiology of invasive and metastatic cancer. A dichotomy is observed in the role of immune cells in bladder cancer. While the immune response defends the host by suppressing neoplastic growth, several immune cells, including neutrophils, macrophages and T-lymphocytes, promote tumor development and progression. The levels of human neutrophil peptide-1, -2 and -3, produced by neutrophils, increase in bladder cancer and might promote tumor angiogenesis and growth. The effect of macrophages is primarily mediated by pro-inflammatory cytokines, IL-6 and TNF-α. In addition, the underlying immunological mechanisms of two treatments, BCG and cytokine gene-modified tumor vaccines, and future directions are critically discussed.
AB - The pathogenesis and transition of normal urothelium into bladder carcinoma are multifactorial processes. Chronic inflammation causes initiation and progression of the underlying pathophysiology of invasive and metastatic cancer. A dichotomy is observed in the role of immune cells in bladder cancer. While the immune response defends the host by suppressing neoplastic growth, several immune cells, including neutrophils, macrophages and T-lymphocytes, promote tumor development and progression. The levels of human neutrophil peptide-1, -2 and -3, produced by neutrophils, increase in bladder cancer and might promote tumor angiogenesis and growth. The effect of macrophages is primarily mediated by pro-inflammatory cytokines, IL-6 and TNF-α. In addition, the underlying immunological mechanisms of two treatments, BCG and cytokine gene-modified tumor vaccines, and future directions are critically discussed.
UR - http://www.scopus.com/inward/record.url?scp=84921340375&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84921340375&partnerID=8YFLogxK
U2 - 10.1586/1744666X.2015.983082
DO - 10.1586/1744666X.2015.983082
M3 - Review article
C2 - 25391391
AN - SCOPUS:84921340375
VL - 11
SP - 265
EP - 279
JO - Expert Review of Clinical Immunology
JF - Expert Review of Clinical Immunology
SN - 1744-666X
IS - 2
ER -